Form 8-K - Current report:
SEC Accession No. 0001193125-21-196202
Filing Date
2021-06-22
Accepted
2021-06-22 16:09:32
Documents
15
Period of Report
2021-06-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d147985d8k.htm   iXBRL 8-K 25145
2 EX-99.1 d147985dex991.htm EX-99.1 16706
6 GRAPHIC g147985g0622114350478.jpg GRAPHIC 3070
7 GRAPHIC g147985g0622114350977.jpg GRAPHIC 2584
  Complete submission text file 0001193125-21-196202.txt   179212

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA arwr-20210618.xsd EX-101.SCH 2916
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE arwr-20210618_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE arwr-20210618_pre.xml EX-101.PRE 11424
8 EXTRACTED XBRL INSTANCE DOCUMENT d147985d8k_htm.xml XML 3367
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 211035310
SIC: 2834 Pharmaceutical Preparations